CytomX Therapeutics, Inc. — FY2020 Form 10-K
Reporting period: Fiscal year ended December 31, 2020. This is an annual report, not a report for the fourth quarter alone. CytomX is a clinical-stage oncology biotechnology company developing antibody-based therapies using its Probody platform. It had no approved products or product sales; revenue was generated primarily from collaboration agreements.
Financial performance and liquidity
| Metric | 2020 | 2019 |
|---|---|---|
| Revenue | $100.4 million | $57.5 million |
| Research and development expense | $112.9 million | $131.6 million |
| General and administrative expense | $36.0 million | $36.8 million |
| Operating loss | $48.6 million | $110.9 million |
| Net loss | $32.9 million | $102.2 million |
| Net loss per share, basic and diluted | $0.71 | $2.26 |
| Net cash from (used in) operating activities | $5.3 million | $(140.5) million |
- Revenue rose 74.6%, chiefly reflecting a $40 million AbbVie milestone and revenue recognized under the Astellas collaboration. The largest 2020 contributors were Bristol Myers Squibb ($39.6 million), AbbVie ($38.2 million), Astellas ($13.9 million), and Amgen ($8.6 million).
- Net loss narrowed substantially, reflecting higher collaboration revenue, lower R&D spending, and a $13.9 million income tax benefit from CARES Act net operating loss carrybacks. The tax benefit is not a product of operating profitability.
- Operating cash flow turned positive, but was supported in part by a $30.9 million increase in deferred revenue, including partner upfront and milestone payments. It should not be read as evidence of recurring operating cash generation.
- At year-end, cash and cash equivalents were $191.9 million and short-term investments were $124.3 million, totaling $316.1 million; restricted cash was an additional $0.9 million. Current assets were $324.0 million versus current liabilities of $100.9 million. Accumulated deficit was $450.1 million.
- The company disclosed no borrowings in the provided financial statements. It had $24.9 million of operating lease liabilities and $39.5 million in specified contractual obligations, primarily operating leases. The latter excludes uncertain milestone and royalty payments.
- In January and February 2021, CytomX raised approximately $107.7 million net from an underwritten stock offering and full exercise of the underwriters’ option. Management said year-end resources were expected to fund planned operations for at least 12 months from issuance of the financial statements; the subsequent offering added liquidity but diluted shareholders.
Business developments, outlook, and risks
- Pipeline: The company’s internal focus was on praluzatamab ravtansine (CX-2009), a CD166-directed ADC, and partnered CX-2029, a CD71-directed ADC. CX-2009 began a new Phase 2 breast-cancer study in December 2020; CX-2029 entered Phase 2 expansion cohorts across four cancer types. Initial data for both were expected in Q4 2021.
- Pacmilimab (CX-072), a PD-L1 Probody, was being studied with CX-2009 in TNBC. The company terminated its Phase 2 pacmilimab–ipilimumab melanoma study in March 2020, citing the changing clinical, competitive, and commercial landscape and COVID-19 impacts. Bristol Myers Squibb continued development of CTLA-4 candidates BMS-986249 and BMS-986288.
- CytomX was working toward late-2021 IND filings for preclinical CX-2043 (EpCAM/Trop-1 ADC) and partnered CX-904 (EGFR-CD3 bispecific). These were targets, not guaranteed milestones. No formal revenue or profitability guidance was provided.
- Safety and trial uncertainty: Reported CX-2009 risks included dose-related ocular toxicity associated with its DM4 payload. CX-2029 was generally tolerated at doses up to 3 mg/kg in the reported study, with anemia, neutropenia/leukopenia, and infusion reactions; anemia’s cause was still under investigation. Early clinical results are preliminary and may change with additional data.
- COVID-19: The pandemic disrupted research and clinical operations, temporarily pausing enrollment and site activation in an earlier CX-2009 Phase 2 study and reducing laboratory activity. Further trial, manufacturing, and recruitment effects remained uncertain.
- Funding and execution: CytomX expected significant future losses and stated it would need additional funding. Clinical development, regulatory approval, scale-up manufacturing, and commercialization remain uncertain; it relies on collaborators and third-party manufacturers, including sole-source suppliers, and had previously experienced a pacmilimab manufacturing failure.
- Contingencies: Vytacera Bio’s patent-infringement suit, filed in 2020, sought unspecified damages; CytomX said it would defend the case and recorded no accrual because the potential loss could not be reasonably estimated. A separate securities class action was dismissed without prejudice in January 2021.
Material changes versus 2019
- Revenue increased by $42.9 million, primarily from the AbbVie dose-escalation milestone, Astellas agreement revenue, and increased Amgen revenue; BMS revenue declined from 2019, which included revenue following termination of certain targets.
- R&D expense declined $18.7 million, mainly due to reduced clinical activity and the termination or reprioritization of programs, partly offset by spending on other partnered and preclinical programs.
- Cash, cash equivalents, and short-term investments increased to $316.1 million from $296.1 million. The company also completed a significant equity offering after year-end.
Key facts for investors to verify
- Whether Q4 2021 CX-2009 and CX-2029 data were delivered, and how efficacy, durability, enrollment, and safety compare with the preliminary findings described here.
- Current cash burn and runway, including the effect of the 2021 equity offering, continuing trial costs, collaboration receipts, and deferred-revenue recognition.
- Progress toward the planned CX-2043 and CX-904 IND filings and any changes to the clinical pipeline or partner programs.
- Updates on CX-2009 ocular events and CX-2029 anemia, neutropenia, dosing, and the clinical relevance of the reported responses.
- Developments in the Vytacera litigation, manufacturing capacity and supply continuity, and any further impact of COVID-19 on trials.
- Future dilution and the terms and economics of collaborations, including milestones, royalties, shared development costs, and partners’ decisions to continue programs.